Retrospective study observes rare toxicities beyond two weeks after BCMA CAR T therapy in multiple myeloma, suggesting a shorter monitoring window may be safe.
Key Points
Severe toxicities emerge early after chimeric antigen receptor T-cell therapy, while cytokine release syndrome rarely develops beyond two weeks post-infusion.
Zero percent of recipients experienced cytokine release syndrome after two weeks, and late immune effector cell-associated neurotoxicity syndrome occurred in 1.6 percent.
Retrospective study across four centers tracked idecabtagene vicleucel outcomes, highlighting infection risks and non-relapse mortality beyond the acute window.